Overview

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
0
Participant gender:
Female
Summary
DCb (docetaxel/carboplatin) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.Combination of anti-angiogenesis inhibitors is expected to further improvePathologic Complete Response(PCR).This study is to evaluate the efficacy and safety of ADCb (Anlotinib/docetaxel/carboplatin) as Neoadjuvant Treatment in Triple-Negative breast cancer. The endpoint of PCR is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Anqin Zhang
Criteria
Inclusion Criteria:

1. Female, aged 18 Years to 75 Years

2. Signed written informed consent approved by the study site Ethics Committee

3. Histologically confirmed Triple-Negative invasive breast carcinoma:Pathologically
confirmed as triple negative, defined as ER and PR expression both < 1 % of tumor cell
nuclei per ASCO/CAP guidelinesa and HER2 negative per ASCO/CAP guidelinesa (IHC 0 or
1+ or FISH-, or IHC 2+ and FISH-)

4. Stage at presentation: II - III (T1cN1-2 or T2-4N0-2)

5. Patients must have measurable disease as defined by palpable lesion with caliper
and/or a positive mammogram or ultrasound. Bilateral mammogram is required for study
entry. Baseline measurements of the indicator lesions must be recorded on the Patient
Registration Form. To be valid for baseline, the measurements must have been made
within the 14 days if palpable. If not palpable, a mammogram or MRI must be done
within 14 days. If palpable, a mammogram or MRI must be done within 2 months prior to
study entry. If clinically indicated, x-rays and scans must be done within 28 days of
study entry.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 14 days of
study entry

7. Adequate organ function within 2 weeks of study entry:

8. ANC ≥ 1500 cells/μL Platelet count ≥ 100,000 cells/μL Hemoglobin ≥ 9 g/dL; patients
may receive red blood cell transfusions to obtain this level Serum creatinine ≤ 1.5 ×
upper limit of normal (ULN) INR and (activated) partial thromboplastin time (aPTT/PTT)
≤ 1.5 ×ULN AST and ALT ≤ULN Serum total bilirubin ≤ ULN, except for patients with
Gilbert's syndrome for whom direct bilirubin should be within the normal range Serum
alkaline phosphatase ≤ULN

9. Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to the start of treatment

10. Women of childbearing potential must agree to use adequate contraception (barrier
method of birth control) prior to study entry and for the duration of study
participation

Exclusion Criteria:

1. Stage IV (metastatic) breast cancer

2. Patients with a history of invasive breast cancer.

3. Patients with a history of ductal carcinoma in situ (DCIS), except for patients
treated exclusively with mastectomy > 5 years prior to diagnosis of current breast
cancer

4. Patients with bilateral breast cancer

5. Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent,
targeted therapy or radiation therapy for current breast cancer.

6. Patients who have undergone incisional and/or excisional biopsy of primary tumor
and/or axillary lymph nodes

7. History of previous or current malignancy at other sites with the exception of
adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma
of the skin. Patients with a history of other malignancies, who remain disease free
for greater than five years are eligible.

8. Current severe, uncontrolled systemic disease that may interfere with planned
treatment (e.g., clinically significant cardiovascular, pulmonary, or metabolic
disease; wound-healing disorders)

9. Major surgical procedure unrelated to breast cancer or significant traumatic injury
within 28 days prior to randomization or anticipation of the need for major surgery
during the course of study treatment

10. Current pregnancy and/or breastfeeding